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Background: Physical forces have been widely used to stimulate bone growth in fracture repair. Addition of bone
growth stimulation to the conservative treatment regime is more costly than standard health care. However, it
might lead to cost-savings due to a reduction of the total amount of working days lost. This economic evaluation
was performed to assess the cost-effectiveness of Pulsed Electromagnetic Fields (PEMF) compared to standard
health care in the treatment of acute scaphoid fractures.
Methods: An economic evaluation was carried out from a societal perspective, alongside a double-blind,
randomized, placebo-controlled, multicenter trial involving five centres in the Netherlands. One hundred and
two patients with a clinically and radiographically proven fracture of the scaphoid were included in the study
and randomly allocated to either active bone growth stimulation or standard health care, using a placebo. All
costs (medical costs and costs due to productivity loss) were measured during one year follow up. Functional
outcome and general health related quality of life were assessed by the EuroQol-5D and PRWHE (patient rated
wrist and hand evaluation) questionnaires. Utility scores were derived from the EuroQol-5D.
Results: The average total number of working days lost was lower in the active PEMF group (9.82 days)
compared to the placebo group (12.91 days) (p = 0.651). Total medical costs of the intervention group (€1594)
were significantly higher compared to the standard health care (€875). The total amount of mean QALY’s
(quality-adjusted life year) for the active PEMF group was 0.84 and 0.85 for the control group. The cost-
effectiveness plane shows that the majority of all cost-effectiveness ratios fall into the quadrant where PEMF is
not only less effective in terms of QALY’s but also more costly.
Conclusion: This study demonstrates that the desired effects in terms of cost-effectiveness are not met. When
comparing the effects of PEMF to standard health care in terms of QALY’s, PEMF cannot be considered a cost-effective
treatment for acute fractures of the scaphoid bone.
Trial registration: Netherlands Trial Register (NTR): NTR2064
Keywords: Scaphoid, Pulsed electromagnetic fields, Acute fractures, Cost-effectiveness analysis, Cost-utility analysis,
Functional outcome* Correspondence: pfwhannemann@gmail.com
1Department of Surgery and Traumasurgery, Maastricht University Medical
Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands
Full list of author information is available at the end of the article
© 2015 Hannemann et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Hannemann et al. BMC Musculoskeletal Disorders  (2015) 16:84 Page 2 of 10Background
The scaphoid has an essential role in proper functional-
ity of the wrist. Fractures of the scaphoid bone are the
most common fracture of the carpus, counting for up to
90% of all carpal fractures and 2% - 6% of all fractures in
the Netherlands [1,2]. In Western countries the annual
incidence rate of scaphoid fractures is estimated between
2.9 - 5 cases per 10.000 inhabitants [3-5]. Usually, scaph-
oid fractures are initially diagnosed on conventional ra-
diographs. However, diagnosis of a scaphoid fracture can
be challenging, since non- and minimally displaced frac-
tures are often not apparent in first instance on radio-
graphs. Timely diagnosis and accurate follow-up with
the use of other diagnostic modalities, like CT-scanning,
and appropriate immobilization can decrease the likeli-
hood of occurrence of adverse outcomes like nonunion
and early osteoarthritis [1,6-9]. Furthermore, delayed
union leads to longer immobilization and prolonged
functional deficit. Since mainly the young and working
population is affected, prolonged cast immobilization
leads to more working days lost with socio-economic
consequences. A previous study showed that even un-
complicated healing leads to a mean total of 155 work-
ing days lost, increasing to 296 days in case of
complicated healing, for instance because of nonunion
[2].
Physical forces (low intensity pulsed ultrasound
(LIPUS) or pulsed electromagnetic field (PEMF)) have
been widely used to accelerate fracture repair in delayed
union [10]. It is thought to reduce osteoclast resorption,
to induce osteoid formation and to stimulate angiogen-
esis [11]. Evidence has accumulated over the past two
decades that physical forces can also be used in the
treatment of acute fractures, shortening time to union
by 30% and reducing nonunion within 12 weeks of initi-
ation of therapy by 71% [12-14].
Implementation of PEMF to the conservative treatment
protocol of scaphoid fractures is more costly compared to
standard care. However, it might lead to cost-savings due
to a reduction of the total amount of working days lost.
Therefore it is necessary to assess whether PEMF stimu-
lation is a cost-effective treatment for acute scaphoid
fractures.
This paper reports the results of our economic evalu-
ation, performed alongside a large double-blind, ran-
domized, placebo-controlled, multicenter trial in which
the costs and effectiveness of PEMF are compared with
standard care in conservatively treated acute fractures of
the scaphoid bone.
Methods
We performed an economic evaluation alongside a
double-blind, randomized, placebo-controlled, multicen-
ter trial involving five centres in the Netherlands, toestablish the cost-effectiveness of pulsed electromagnetic
fields (PEMF) in the treatment of acute scaphoid frac-
tures. The clinical and radiological outcomes of the trial
have been reported in detail elsewhere [15].
For the economic evaluation we used data from our
randomized controlled trial and focused on functional
outcome, costs and cost-effectiveness. The time horizon
was similar to the clinical study from the moment of in-
clusion until 12 months follow-up.
Approval was obtained from the coordinating ethics
review committee (Independent Review Board Nijmegen,
The Netherlands) and each participating centre (Maastricht
University Medical Centre, Maastricht, The Netherlands;
Rijnstate Hospital, Arnhem, The Netherlands; Canisius
Wilhelmina Hospital, Nijmegen, The Netherlands; Isala
Clinics, Zwolle, The Netherlands; Maasziekenhuis Pantein
Hospital, Boxmeer, The Netherlands). Written informed
consent for participation was obtained from every patient.
Patients
All patients > = 18 years of age diagnosed between January
1st 2010 and December 31st 2011 with an acute, unilat-
eral undisplaced fracture of the scaphoid types A1, A2,
B1 or B2 according to the Herbert classification [16],
were included in the trial. Exclusion criteria were: dis-
placed scaphoid fractures, proximal pole scaphoid frac-
tures (Herbert type B3), fracture dislocations of the
carpus or comminuted scaphoid fractures (Herbert type
B4 and B5 fractures), presentation > five days after in-
jury, additional fractures of the wrist, carpal or metacar-
pal bones, a pre-existing impairment of wrist function,
pregnancy and presence of a life-supporting implanted
electronic device. All scaphoid fractures were diagnosed
by a combination of physical examination and radio-
graphic imaging (conventional scaphoid series and CT
scan) at the time of trauma. All included fractures were
classified according to a CT-based modified Herbert
classification [17]. All fractures were treated conserva-
tively with immobilization in a below elbow cast with
the first metacarpal and proximal phalanx immobilized.
Electromagnetic stimulation was administered continu-
ously for 24 hours a day using a PEMF bone growth
stimulator incorporated into the cast (Orthopulse III®
PEMF bone growth stimulator, Ossatec®, Uden, The
Netherlands). The signal characteristics of the PEMF
device used in our study were: pulse amplitude 50 mV,
pulse width 5 μs, burst width 5 ms, burst refractory
period 62 ms, repetition rate 15 Hz. Half of the PEMF-
devices were randomly disabled in the factory. Identical
devices and the same follow-up protocol were used for
both control and PEMF cases. Neither the investigators
nor the patients were aware of the device’s functionality.
The PEMF device was removed six weeks after the
start of treatment. The patients underwent clinical and
Table 1 Costs per unit [21]




PEMF device 665.90 665.90
Application of a cast 31.25 31.25








Outpatient clinic visit 70.06 65.46
*Costs are indexed to 2011 and given in Euro.
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structed CT scans) at 6, 9, 12, 24 and 52 weeks after the
start of treatment. In patients with complete clinical and
radiological union, the cast was removed at six, 9 or
12 weeks, depending on the time of union.
We hypothesized that PEMF would reduce the time to
union by up to 30% with subsequent shortening of time
off work [13]. Based on this information we conducted a
power analysis with a two-sided significance level (alpha,
type I error) of 0.05 and an assumed power (1-beta) ofFigure 1 Consort flow diagram.0.8. This resulted in a total study group of 100 patients,
with a sample size of 50 patients per group [18].
Functional and quality of life outcomes
All patients were required to fill in three questionnaires
at baseline, 6, 9, 12, 24 and 52 weeks after the scaphoid
fracture was diagnosed. The Patient Rated Wrist/Hand
Evaluation (PRWHE) was used to assess the level of
fracture related functional deficit and pain level from the
patient’s perspective. The PRWHE is a 15-item question-
naire that allows patients to rate the level of wrist pain
and disability in activities of daily living via a 10-point
categorical scale from 0 (no pain/difficulty) to 10 (worst
pain ever/unable to do) [19]. The EuroQol-5-D ques-
tionnaire was used for quality of life assessment through
measurement of the following six dimensions: mobility,
self-care, usual activities, pain/discomfort, anxiety/
depression and the visual analogue scale (VAS) [20].
Costs
Costs were collected from the first outpatient visit until
12 months follow up and included all costs in- and outside
health care. Cost analysis within health care included
costs of the intervention (i.e. device, application and
removal of a plaster cast), wrist/scaphoid X-rays, wrist/
scaphoid CT-scans, emergency visits and outpatient
Table 3 Assessment of functional outcome according to
the Patient-Rated Hand/Wrist Evaluation (PRWHE)
Variable Group A (Active) Group B (Placebo) p-value
Pain Subscale*
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pital information systems of the different hospitals.
The costs per unit were derived from the financial de-
partment of our hospital and the Dutch guidelines for
cost-calculations in health care [21]. Diagnostic tests
(conventional radiographs and CT-scans) and outpatient
clinic visits are more costly in university hospitals;
therefore university and general hospital prices were
used separately.
Costs concerning outside health care included prod-
uctivity costs, as measured by the number of working
days lost determined at baseline and 12, 24 and 52 weeks
after inclusion, by the PRODISQ-questionnaire (PROd-
uctivity and DISease Questionnaire) [22]. The costs of
productivity loss were calculated by means of the friction
cost method, based on the average standardized wages
per hour [21]. The basic idea of the friction cost method
is that the amount of production lost due to disease de-
pends on the time-span organizations need to restore
the production at the initial production level [23].
No discounting was applied, since all data with regard
to the costs and effectiveness were collected within one
year. All costs are indexed to 2011. Table 1 provides an






Age – year* 35 (18 - 70) 34 (18 - 77)
Days between fracture and start of
treatment*
4.25 (0 - 5) 3.69 (0 - 5)
Male (n, %) 40 (78) 38 (75)
Fracture in dominant hand (n,%) 28 (55) 29 (57)
Anatomical snuff box tenderness
(n, %)
46 (90) 49 (96)
Pain with longitudinal compression
(n, %)
39 (77) 45 (88)
Fracture type [17] (n, %)
- Tubercle (A1) 9 (18) 9 (18)
- Transverse waist, undisplaced (A2) 19 (37) 20 (39)
- Oblique (B1) 15 (29) 18 (35)
- Transverse waist with distraction (B2) 8 (16) 4 (8)
Comorbidities (n, %)
- None 34 (67) 38 (75)
- Osteoporosis 0 (0) 0 (0)
- Corticosteroids 0 (0) 1 (2)
- Multiple 1 (2) 1 (2)
Smoking (n, %) 16 (31) 11 (22)
*Variables are denoted as mean (range).
No significant differences were seen between groups.Economic evaluation
The economic evaluation was performed from a societal
perspective and includes a cost-utility analysis. The in-
cremental costs per QALY (quality-adjusted life year),
usually interpreted as the additional costs of PEMF to
gain one additional QALY compared to standard care,
were calculated. A QALY is calculated by multiplying
the utility of being in a certain health state by the time a
patient experiences that health state. Utility scores were
derived from the EuroQol-5D and converted to utility
scores by the UK Dolan algorithm [24].
Statistical methods
Statistical analysis was performed using proprietary stat-
istical software with advanced statistics add-on modules
(SPSS statistical package version 20.0; SPSS inc, 233S
Wacker Drive, Chicago, 60606 Illinois, United States). A
statistician blinded from treatment allocation was re-
cruited for analysis of the clinical data. P-values < 0.05(mean, [95% CI**])
- Baseline 25.7 [21.4; 30.0] 26.8 [22.7; 31.0] 0.708
- 6 weeks 16.0 [12.4; 19.5] 15.4 [11.3; 19.4] 0.824
- 9 weeks 14.6 [11.1; 18.0] 15.4 [11.1; 19.6] 0.770
- 12 weeks 10.7 [7.4; 14.0] 10.2 [6.6; 13.9] 0.851
- 24 weeks 8.3 [4.9; 11.7] 7.2 [4.3; 10.1] 0.631
- 52 weeks 4.6 [2.1; 7.1] 3.7 [1.1; 6.3] 0.626
Function Subscale†
(mean, [95% CI**])
- Baseline 74.3 [67.9; 81.0] 68.1 [59.8; 76.3] 0.235
- 6 weeks 52.2 [44.3; 60.1] 47.5 [38.4; 56.5] 0.426
- 9 weeks 29.3 [21.0; 37.6] 34.9 [23.5; 46.3] 0.411
- 12 weeks 16.6 [9.3; 23.9] 20.8 [12.2; 29.3] 0.456
- 24 weeks 8.1 [4.0; 12.1] 6.4 [2.1; 10.7] 0.569
- 52 weeks 2.8 [0.8; 4.7] 3.4 [0.5; 6.2] 0.724
Total Score‡
(mean, [95% CI**])
- Baseline 62.9 [56.5; 69.3] 60.9 [53.1; 68.7] 0.687
- 6 weeks 42.1 [35.5; 48.7] 39.1 [31.0; 47.2] 0.565
- 9 weeks 29.2 [22.1; 36.4] 32.8 [23.4; 42.2] 0.531
- 12 weeks 19.0 [12.6; 25.4] 20.6 [13.2; 28.0] 0.738
- 24 weeks 12.3 [7.1; 17.6] 10.4 [5.7; 15.1] 0.586
- 52 weeks 5.9 [2.7; 9.2] 5.4 [1.5; 9.3] 0.832
*Best possible outcome (no pain) = 0, worst possible outcome = 50.
**CI, confidence interval.
†Best possible outcome (no functional disability) = 0, worst
possible outcome = 100.
‡Best possible outcome (no pain & no functional disability) = 0, worst
possible outcome = 100.








- Baseline 49.35 43.52 0.052
- 6 weeks 43.28 39.54 0.115
- 9 weeks 39.19 38.76 0.848
- 12 weeks 38.00 37.00 0.646
- 24 weeks 37.54 36.54 0.597
- 52 weeks 36.34 34.50 0.191
Self-Care* (mean
rank**)
- Baseline 51.34 41.44 0.039
- 6 weeks 44.51 37.22 0.111
- 9 weeks 37.24 41.22 0.340
- 12 weeks 37.42 37.58 0.960
- 24 weeks 37.00 37.00 1.00
- 52 weeks 35.29 35.00 0.359
Usual activities*
(mean rank**)
- Baseline 48.6 44.3 0.373
- 6 weeks 42.3 40.6 0.704
- 9 weeks 38.9 39.2 0.945
- 12 weeks 35.9 39.1 0.441
- 24 weeks 38.4 35.5 0.309
- 52 weeks 37.0 33.7 0.215
Pain/discomfort*
(mean rank**)
- Baseline 49.3 43.6 0.250
- 6 weeks 44.3 38.4 0.195
- 9 weeks 39.1 37.8 0.769
- 12 weeks 39.4 35.7 0.379
- 24 weeks 40.7 33.2 0.051
- 52 weeks 37.3 33.4 0.234
Anxiety/depression*
(mean rank**)
- Baseline 47.8 45.1 0.339
- 6 weeks 40.9 42.2 0.625
- 9 weeks 37.8 40.5 0.251
- 12 weeks 35.5 39.5 0.091
- 24 weeks 35.0 39.1 0.038
- 52 weeks 34.4 36.8 0.229
VAS-score†
(mean, [95% CI‡])
- Baseline 72.5 [65.9; 79.0] 78.7 [73.9; 83.4] 0.126
- 6 weeks 78.0 [73.8; 82.3] 82.6 [78.4; 86.8] 0.127
- 9 weeks 82.2 [78.3; 86.1] 82.2 [77.2; 87.3] 0.987
Table 4 Assessment of functional outcome according to
the EuroQoL-5D (Continued)
- 12 weeks 84.8 [80.7; 89.0] 82.9 [77.6; 88.3] 0.576
- 24 weeks 88.1 [83.9; 92.2] 88.7 [85.0; 92.4] 0.818
- 52 weeks 87.9 [84.1; 91.8] 90.8 [87.0; 94.7] 0.282
*Mann Whitney U test; p < 0.05.
**Scores are presented as mean rank. The higher the score, the more
problems experienced with activities of daily living.
†All variables are denoted as a score between 0-100, with 100 being the best
possible outcome.
‡CI, confidence interval.
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case of normal distribution an independent student’s t-
test was performed, to compare means between the
intervention and control group. The non-parametric
Mann-Whitney U-test was used in case of ordinal vari-
ables and in cases where normality could not be
assumed.
In case of missing values, a multiple imputation model
was used to analyze and complete the dataset. Missing
values were below 30% for all variables. Multiple imputa-
tions for missing values concerning the questionnaires
were performed using all baseline characteristics (age,
sex, type of fracture, hand dominance and comorbidity)
and existing variables of the EuroQol-5D and PRWHE.
For each missing value, 5 imputations according to the
Bayesian probability rules were performed. In addition,
multiple imputations were performed for missing data
on the productivity loss, again using all baseline charac-
teristics as stated above.
Since cost data generally have a highly skewed distri-
bution, we performed a non-parametric bootstrap ana-
lysis (1000 replications) to estimate uncertainty intervals
around the difference in mean costs and to quantify the
uncertainty surrounding the incremental cost-
effectiveness ratio (ICER) [25,26]. The bootstrap analysis
was performed in Microsoft Excel. Results of the boot-
strap analysis regarding the effectiveness and costs were
presented in a cost-effectiveness plane and an acceptabil-
ity curve. The cost-effectiveness plane is a graphical
presentation of four quadrants in which the additional
costs and QALY’s of a new therapy (active PEMF) are
compared to standard care. The cost-effectiveness ac-
ceptability curve shows the probability of PEMF being
more cost-effective compared to standard care. All pa-




A total of 117 patients were eligible for inclusion; 12 pa-
tients withdrew, for two patients a primary indication
for operation was set and one patient was not mentally
fit enough to participate in the study. Therefore, 102


















€2827 €2253 €574 [-423; 1438]
*Costs are denoted in Euro.
**CI, confidence interval.
***Numbers do not exactly add up due to the bootstrap analysis.
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scaphoid fracture were included in the study and ran-
domly allocated to either active PEMF treatment (n =
51) or placebo treatment (n = 51) (Figure 1). The two
groups were similar concerning baseline characteristics
(Table 2).
Clinical effect
Results from our recently published clinical study showed
no overall positive effect of adding PEMF to the conserva-
tive treatment of acute scaphoid fractures [15]. However,
the use of PEMF in A2 type scaphoid fractures revealed a
significantly shorter time to union [15]. Therefore, PEMF
might accelerate union in a well-defined subgroup of stable,
undisplaced scaphoid waist fractures.
For the PRWHE no significant differences were found
between the active PEMF group and the control group
at any of the time points (Table 3). Concerning Self-Care
and Anxiety/Depression, both variables of the EuroQol-
5D, we found a significant difference at respectively
baseline and 24 weeks. For the other variables of the
EuroQol-5D there were no significant differences at any
of the time points (Table 4).
Costs
The mean total health care costs per patient were
€875 in the placebo group and €1594 in the active
PEMF group (Table 5). This difference in costs was
statistically significant (€719, 95% CI €652 to €772)
(Table 6) and could be attributed entirely to the use of
the PEMF device.
Concerning productivity loss the average total number
















PEMF device 1.0 665.90 0 0
Application of a cast 2.61 81.50 2.53 79.04




1.0 30.85 1.0 31.15
Wrist / scaphoid CT
scan
2.95 276.78 2.65 255.35
Emergency
department visit
1.0 154.45 1.0 154.45




*Costs are indexed to 2011 and denoted in Euro.
**Total health care costs do not exactly add up due to the bootstrap analysis.(9.82 days) compared to the placebo group (12.91 days).
However, this difference was not statistically significant
(p = 0.651). When including costs due to productivity
loss in the cost-analysis, mean total costs for the active
PEMF group are higher (€2827) compared to mean total
costs for the standard treatment (€2253), although this
difference is not statistically significant (difference = €574,
95% CI = €-423 to €1438) (Table 6).
When excluding patients from the analysis that were
student or unemployed (17 in the active PEMF group
and 12 in the placebo group, p = 0.27), mean total costs
for the active PEMF group are still higher (€3305) com-
pared to mean total costs for the standard treatment
(€2634) (difference = €670, 95% CI = €-405 to €1732)
(Table 7).
Cost-effectiveness
The mean QALY was 0.84 for the active PEMF group
and 0.85 for the control group, resulting in a non-
significant difference of 0.01 (95% CI = -0.01;0.04)
(Table 8). The cost-effectiveness plane (Figure 2) shows
that the majority of all cost-effectiveness ratios (85%) fall
into the north-western quadrant where PEMF is less ef-
fective in terms of QALY’s and more costly. When only
considering patients with a paid job, the difference in















€1747 €1798 €-51 [-1119; 975]
Total societal
costs***
€3305 €2634 €670 [-405; 1732]
*Costs are denoted in Euro.
**CI, confidence interval.
***Numbers do not exactly add up due to the bootstrap analysis.
Table 8 Incremental cost-effectiveness ratio of PEMF vs.
standard treatment for acute scaphoid fractures
Costs* QALY ICER
Group A (Active) €2827 0.84
Group B (Placebo) €2253 0.8545
Increment €574 -0.0145 inferior
*Costs are denoted in Euro.
QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio.
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results in an incremental cost-effectiveness ratio of
€113559 per QALY gained which is unlikely to be con-
sidered cost-effective (Table 9). In addition, the cost-
effectiveness plane shows that although 64% of the cost-
effectiveness pairs are located in the north-eastern quad-
rant where active PEMF treatment leads to more effect
against more costs, 29% is situated in the quadrant
where PEMF is less effective and more costly (Figure 3)
The acceptability curve (Figure 4) shows that even for a
threshold up to €70000, there is only a 40% probability
that PEMF is more cost-effective compared to standard
care.Discussion
Data about the amount of working days lost due to
scaphoid fractures is limited. The most detailed source is
a previously published prospective study that assessed,
among other things, time off work due to carpal injuries
in the Netherlands in the period from 1990 to 1993 [2].
In this study the mean total time off work for conserva-
tively treated fractures of the scaphoid was 144 days with
a range of 12 to 1353 days. In our trial the mean total
number of working days lost was remarkably lower, 9.82
working days in the active PEMF group compared to
12.91 working days lost in the control group with a
range of 0 to 190 days.Figure 2 Cost-effectiveness plane for the incremental costs per QALY (basIn the study by van der Molen et al. [2] the majority of
the included patients (94%) performed manual work
whereby they needed both hands for their job. Only 2%
of the study population was able to resume their previ-
ous job with an immobilized wrist. All 533 patients were
off work for at least one day.
In contrast, in our study 55% of the included patients
performed manual work and 49% of the responders with
a paid job resumed their jobs immediately with an
immobilized wrist and therefore had no working days
lost. This suggests that the most important factor influ-
encing time off work among patients with immobilized
wrists due to carpal injuries is the patient’s occupation.
In accordance with other authors, we concluded that
non-manual workers had less time off work than manual
workers [27].
The average total number of working days lost was
lower in the active PEMF group compared to the pla-
cebo group. However, we could only retrieve informa-
tion concerning the number of working days lost in 73%
of the study population. In total, 49 out of 74 patients
had no working days lost; 26 out of 39 patients in the
active group compared to 23 out of 35 patients in the
control group. Since 49% of the responders with a paid
job was able to return to their previous job immediately,
and only 11% was off work for more than one month,
the costs due to productivity loss were less than we ori-
ginally expected on basis of previously best available evi-
dence from van der Molen et al. [2]. Moreover, this
study was based on data from 1991 to 1993. Properties
and demands regarding manual work have changed over
this period of almost 20 years.
A number of patients were student or unemployed
and therefore not generating a loss in working days in
the context of a paid job. Although the difference in un-
employed patients between groups was not statistically
different (p = 0.27), we also calculated costs due toed on EuroQol-5D).
Table 9 Incremental cost-effectiveness ratio of PEMF vs.
standard treatment for acute scaphoid fractures for
working patients only
Costs* QALY ICER
Group A (Active) €3305 0.8474
Group B (Placebo) €2634 0.8415
Increment €670 0.0059 113559
*Costs are denoted in Euro.
QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio.
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only. Obviously, the number of working days lost was
higher amongst working patients (15.32 days in the
PEMF group vs. 18.83 days in the placebo group, p =
0.73) resulting in higher costs due to loss of productivity.
However, mean total costs were still higher in the PEMF
group. Combining the costs and effects for the subgroup
of working patients resulted in an incremental cost-
effectiveness ratio of €113559 per QALY gained which is
unlikely to be considered cost-effective given the com-
monly applied Dutch threshold value of €40000 [28].
Our research group performed the first CT-scan evalu-
ated, double-blind, randomized, placebo-controlled trial
to investigate the effect of PEMF bone growth stimula-
tion on the time to union, functional outcome and cost-
effectiveness of acute fractures of the scaphoid. We
found no conclusive evidence supporting the implemen-
tation of PEMF stimulation to the conservative treat-
ment regime [15,29]. As reported in our recently
published study concerning the clinical section of the
study, the addition of PEMF stimulation to the conserva-
tive treatment of acute scaphoid fractures might acceler-
ate union in a well-defined subgroup of stable
undisplaced scaphoid waist fractures [15]. However, it
does not improve overall functional and radiological out-
comes of conservatively treated scaphoid fractures.
These results are not consistent with the results ofFigure 3 Cost-effectiveness plane for the incremental costs per QALY (basformer acute fracture studies on the use of electrical
bone growth stimulation. Heckman et al. reported in a
randomized controlled trial concerning addition of
LIPUS to the treatment protocol of acute diaphyseal
tibia fractures, a significant decrease in time to union
(p = 0.0001) and substantial cost-savings [12]. Kristian-
sen et al. compared LIPUS with standard care in non-
operatively treated extra-articular distal radius frac-
tures. The time to union was accelerated by 37 days
(p < 0.0001) and LIPUS treatment was associated with
a significantly smaller loss of reduction (p < 0.01) [14].
Mayr et al. reported on acute nondisplaced scaphoid
fractures (Herbert B1 and B2) treated with LIPUS. Re-
sults showed a significant acceleration of the fracture-
healing process by 17 days (p < 0.01). Furthermore,
there was significantly more trabecular bridging after
six weeks in the LIPUS group (81,2%) compared to the
placebo group (54,6%) [13].
A possible explanation for the difference in clinical
outcome compared to previous literature and a limita-
tion of our study may be the large heterogeneity of our
study group, since we included different types of scaph-
oid fractures (Herbert types A1, A2, B1 and B2). Post-
hoc log-rank analysis of all data from our recently pub-
lished clinical study revealed a significantly shorter time
to union in the active PEMF group for undisplaced
transverse scaphoid waist fractures (Herbert type A2
fractures) [15,16]. PEMF bone growth stimulation seems
to have an accelerating effect on union in stable scaph-
oid waist fractures. Since unstable fractures are more
likely to progress to nonunion, we think that stability of
the fracture pattern may play a crucial role in predicting
the effect of PEMF bone growth stimulation in scaphoid
waist fractures. Therefore, electrical bone growth stimu-
lation might be only effective in a well-defined subgroup
of stable scaphoid fractures. Future studies should focus
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Figure 4 Cost-effectieveness acceptability curve (based on EuroQol-5D)
for working patients only.
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therefore justified among patients with this type of frac-
ture. This seems particularly relevant since recent re-
search has shown that the majority of scaphoid waist
fractures are undisplaced [30].
Concerning the functional outcome as measured by
the PRWHE questionnaire and general health related
quality of life, as measured by the EuroQol-5D, we found
no significant differences between the active PEMF
group and the control group. Our cost-effectiveness ana-
lysis shows that PEMF stimulation significantly increases
treatment costs against no significant improvement of
general health related quality of life.
Conclusions
In conclusion, evidence from our clinical trial has not
demonstrated sufficient advantage to warrant routine
use of PEMF, although PEMF might accelerate union in
a well-defined subgroup of stable, undisplaced scaphoid
waist fractures. From a societal perspective, we conclude
that the desired effects in terms of cost-effectiveness are
not met. When comparing the effects of PEMF to pla-
cebo expressed in QALY’s, PEMF cannot be considered
a cost-effective treatment for acute fractures of the
scaphoid bone in general.
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